Showing results (201-210 of 235) with videos related to
Sort By:
Pageof 24
Blood|September 22, 2020
Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosisPeter G Miller, Adam S Sperling, Christopher J Gibson, et al.Blood Advances|July 18, 2022
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myelomaElizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, et al.Oxidative Medicine and Cellular Longevity|August 12, 2022
Targeting Oxidative Stress Mechanisms to Treat Alzheimer's and Parkinson's Disease: A Critical ReviewAbdullahi Tunde Aborode, Manas Pustake, Wireko Andrew Awuah, et al.JCO Oncology Practice|April 2, 2021
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN)Joshua A Roth, Meghna S Trivedi, Stacy W Gray, et al.Cell Stem Cell|October 20, 2023
SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulationChun-Wei Chen, Linda Zhang, Ravi Dutta, et al.Genes|January 28, 2026
Optical Genome Mapping Enhances Structural Variant Detection and Refines Risk Stratification in Chronic Lymphocytic LeukemiaSoma Roy Chakraborty, Michelle A Bickford, Narcisa A Smuliac, et al.Blood|May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogsAdam S Sperling, Michael Burgess, Hasmik Keshishian, et al.Blood Cancer Discovery|October 17, 2025
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3Mariateresa Fulciniti, Yao Yao, Tommaso Perini, et al.Blood|August 18, 2023
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancyPeter G Miller, Adam S Sperling, Christina Mayerhofer, et al.Nature|June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin KMikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.Pageof 24